Therapeutic interventions are available for patients with primary biliary cholangitis

Abstract

The first-line treatment of MM for patients with
primary biliary cholangitis (CEC) currently consists of
ursodeoxycholic acid (UDCA) at 13 to 15 mg/kg per
day, usually divided into two daily doses. It can take up
to 12 months for the UDCA to reach all of its benefits;
however, up to 40% of patients treated with UDCA
will not have an adequate biochemical response after 1
year. In these patients, a farnesoid X receptor agonist
(FXR) (Ocaiva, Intercept) is usually added for secondline
treatment. The double-blind, placebo-controlled,
phase 3, placebo-controlled study showed that UDCAtreated
patients who also received obeticic acid were
about 5 times more likely (46% versus 10% with
placebo) to achieve the goal. Primary compound
(defined as alkaline phosphatase ≤ 1.67 × upper limit
of normal, ≥15% reduction in alkaline phosphatase,
and normalization of bilirubin) than patients treated
with UDCA alone.